Shaping the Future of Infectious Diseases

Half-year results 2026

Webcast presentation | August 18, 2026

David Veitch

Chief Executive Officer

Introduction

Disclaimer

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.

Half-year 2026 – Highlights

Delivering strong financial results and positioning the company for future success

FINANCIALS

Total revenue up 14% y-o-y to **CHF 119 million**

Operating profit increased by 32% y-o-y to CHF 32 million

Net cash position **doubled** y-o-y to CHF 105 million

Awarded USD 61 million of non-dilutive funding from BARDA and CARB-X

PORTFOLIO

Cresemba global in-market sales **increased by 27%** to USD 782 million*

Fosmanogepix: phase 3 on track; BARDA funding tranche secured through enrollment milestone achievement

BAL2420: initiated first-in-human phase 1 study with novel antibiotic

Prokaryotics: entered collaboration to develop a novel broad-spectrum antifungal

*MAT Q1/2025 vs. Q1/2026; MAT: Moving annual total; Source: IQVIA Analytics Link, March 2026

Innovative anti-infective pipeline

Addressing urgent and evolving infection threats



[1]The registration status and approved indications may vary from country to country.
HABP, CABP: Hospital- and community-acquired bacterial pneumonia, SAB: *Staphylococcus aureus* bacteremia, ABSSSI: acute bacterial skin and skin structure infections.

Expanding future pipeline opportunities through early-stage collaborations and partnerships

Phare Bio
Artificial intelligence-powered discovery of novel antibacterial agents

Prokaryotics
Developing novel broad-spectrum antifungal targeting severe invasive infections

Provide access to innovative anti-infective technologies and potential future pipeline opportunities

Adesh Kaul

Chief Financial Officer

Commercial &
Financial Update

Cresemba's in-market sales continue double-digit growth



USD

782 million

April 2025 to March 2026

27%

year-on-year growth

MAT: Moving annual total; Source: IQVIA Analytics Link, March 2026

Zevtera® US launch – Positioned for future success

Launched in the US in July 2025 through commercial partner Innoviva Specialty Therapeutics

- Broad market access established: key GPO listings, J-code, Medicaid/340B and NTAP reimbursement support
- Positive early clinical experience reflected in increasing account ordering and repeat ordering trends with encouraging medical community feedback
- Expanded commercial infrastructure to increase hospital coverage
- Long-term growth opportunity supported by US market exclusivity until April 2034

GPO: Group Purchasing Organizations; NTAP: New Technology Add-on Payment

Capital efficiency
through non-dilutive R&D funding

in USD, rounding consistently applied

by BARDA and CARB-X
Committed

> 440 million

out of which
Awarded

~ 165 million

Non-dilutive funding has a long-term positive effect on value creation and risk mitigation:

- Preserving shareholder value:
  No equity component; no dilution to shareholders
- Increasing return-on-investment:
  Reducing Basilea's share of investment
- Reducing financial risk inherent during development:
  No repayment required

Strong financial results H1 2026 – Significant increase in revenue and profit

in CHF million	H1 2026	H1 2025
Cresemba and Zevtera related revenue	**92.3**	**90.5**
of which royalty income	57.8	52.1
of which milestone and upfront payments	4.7	6.9
Other revenue	26.7	13.5
Total revenue	**119.0**	**104.0**
Cost of products sold	15.4	24.2
Operating expenses	72.0	55.7
Operating profit	**31.6**	**24.0**
Net profit	**27.9**	**15.8**
Cash and cash equivalents and restricted cash (as of June 30, 2026/2025)	**176.0**	**132.7**

Note: Consolidated figures in conformity with US GAAP; rounding applied consistently

Strong cash flows while making significant R&D investments

Cash flows from operating activities (in CHF million)



Note: Consolidated figures in conformity with US GAAP; rounding applied consistently

Strengthening the balance sheet through debt reduction

CHF 150 million debt **reduction** between 2022-2026 (nominal value)



Note: rounding applied consistently

Updated FY 2026 financial guidance – Increase in total revenue driving 40% increase in operating profit

in CHF million	**FY 2026** updated guidance	**FY 2026** previous guidance	**FY 2025** actuals
Cresemba and Zevtera related revenue	~210	~200	194.4
of which royalty income	*~125*	*~120*	*111.6*
Total revenue	**~ 15% increase**	~ 10% increase	**232.4**
Research and development expenses	~ 20% increase	~ 20% increase	105.9
Operating profit	**~ 40% increase**	~ 20% increase	**51.5**

Note: Consistent rounding was applied.

Cresemba and Zevtera related revenue

Revenue mix shifting towards higher margin revenues – increasing cash contribution



Marc Engelhardt

Chief Medical Officer

Portfolio Update

Advancing our phase 3 programs toward approval

Ceftibuten-ledaborbactam:
Phase 3 derisked through well-established study design

- **Global phase 3 program in complicated urinary tract infections[1]**
- **Readout & regulatory process**

Fosmanogepix: Phase 3 derisked through positive real-world data

- **FAST-IC: Global phase 3 in invasive candidiasis and candidemia**
- **FORWARD-IM: Global phase 3 in invasive mold infections**
- **Readout and regulatory process**

2024	2025	2026	2027	2028	2029

[1] Includes pyelonephritis

Fosmanogepix – Phase 3 program on track with growing real-world experience

- Differentiated profile
  - First-in-class mechanism of action
  - Broad-spectrum activity against molds and yeasts
  - Excellent tissue penetration
  - IV and oral formulations
- Phase 3 studies[1] on track
- Clinical experience through Expanded Access Program[2]
  - For patients with serious and/or life-threatening invasive fungal infections and no other available treatment option
  - Nearly 600 patients treated across 22 countries
  - Increasing real-world experience supports development program & future market access



Status on 01 July 2026

[1] ClinicalTrials.gov ID: NCT05421858, NCT06925321;[2] ClinicalTrials.gov ID: NCT06433128

BAL2420 (LptA inhibitor): phase 1 study progressing

First-in-class antibiotic targeting highly resistant Gram-negative bacteria

BAL2420 destroys the LPS transport bridge

The outer cell membrane becomes compromised and LPS accumulate at the inner cell membrane, leading to rapid bacterial cell death.



- Phase 1 first-in-human dose escalation study[1] initiated in Q1 2026 and progressing as planned
- Targeting the most frequent Gram-negative pathogens causing infections (Enterobacteriaceae), including carbapenem-resistant isolates
- Novel mechanism targeting LPS transport in Gram-negative bacteria

[1] ClinicalTrials.gov ID: NCT07500181

Additional pipeline assets supporting future growth

Antibacterial and antifungal assets

Ceftibuten-ledaborbactam

Phase 3 candidate

- Potential first oral BL/BLI combination for complicated urinary tract infections
- Addresses multidrug-resistant Gram-negative infections
- FDA Fast Track and QIDP designations[1]
- Phase 3 preparations progressing for planned start mid-2027

BAL2062

Phase 2 candidate

- Novel antifungal for invasive aspergillosis, including resistant strains
- New mode of action with potential efficacy advantages
- Encouraging phase 1 safety and tolerability profile
- Regulatory pathway discussions ongoing

Beta lactam/beta lactamase inhibitor (BL/BLI)

[1] QIDP and Fast Track designations by the FDA for cUTI and uncomplicated urinary tract infections.

David Veitch

Chief Executive Officer

“Agenda 2030”
and Summary

Commercial portfolio outlook

Targeting four commercial products by 2030



“Agenda 2030” – Delivery on track

Strong operational execution reinforces confidence in our financial targets

Strong financial position

- CHF 160 million cash as of end-2025
- Approx. CHF 600 million cumulative cash flow from Cresemba and Zevtera from 2026 to 2030
- More than USD 350 million potential non-dilutive funding from existing agreements (awarded and potential future tranches) from 2026 to 2030

This allows us to

- Bring phase 3 programs to market with the potential to double current in-market sales
- Advance early-stage pipeline
- In-license or acquire exciting new assets

We continue to deliver on our goals

- Cresemba & Zevtera revenue
  - ✓ Cresemba global in-market sales continue showing impressive double-digit growth
- Phase-3 programs
  - ✓ Fosmanogepix two phase 3 studies progressing as planned
  - ✓ Preparations on-track for initiating ceftibuten-ledaborbactam phase 3 program mid 2027
- Preclinical and early-stage clinical programs
  - ✓ Initiated phase 1 study with novel antibiotic BAL2420
  - ✓ Entered new collaboration for preclinical development
- Non-dilutive R&D funding for anti-infectives portfolio
  - ✓ Awarded USD 61 million of non-dilutive funding in 2026 for our R&D pipeline programs

Q & A

Capital Markets Day

October 28, 2026

Zürich, Switzerland

Thank you

Glossary

ABSSSI	**A**cute **b**acterial **s**kin and **s**kin **s**tructure **i**nfections
BARDA	**B**iomedical **A**dvanced **R**esearch and **D**evelopment **A**uthority
BL/BLI	**B**eta-**l**actam/**B**eta-**l**actamase **i**nhibitor
CABP	**C**ommunity-**a**cquired **b**acterial **p**neumonia
CARB-X	**C**ombating **A**ntibiotic-**R**esistant **B**acteria Biopharmaceutical **A**ccelerator
CHF	Swiss Franc
cUTI	**C**omplicated **U**rinary **T**ract **I**nfections
EU	**E**uropean **U**nion
FDA	US **F**ood and **D**rug **A**dministration
FY	**F**ull **Y**ear
HABP	**H**ospital-**a**cquired **b**acterial **p**neumonia
GPO	**G**roup **P**urchasing **O**rganizations
IV	**I**ntra**v**enous
LPS	**L**ipo**p**oly**s**accharide
LptA	**L**ipo**p**olysaccharide **t**ransport protein **A**
MAT	**M**oving **A**nnual **T**otal
Mn	Million
NTAP	**N**ew **T**echnology **A**dd-On **P**ayment
QIDP	**Q**ualified **I**nfectious **D**isease **P**roduct
R&D	**R**esearch and **D**evelopment
ROW	**R**est **O**f **W**orld
SAB	***S**taphylococcus **a**ureus* **b**acteremia
US	**U**nited **S**tates
US GAAP	**U**nited **S**tates **G**enerally **A**ccepted **A**ccounting **P**rinciples
USD	**U**nited **S**tates **D**ollar
Y-o-y	year-on-year

Shaping the Future
of Infectious Diseases

Hegenheimermattweg 167b
4123 Allschwil
Switzerland

info@basilea.com
www.basilea.com